Last edition
News about
State of Texas Sues Bristol-Myers Squibb, Sanofi Over Alleged Failure to Disclose Plavix Efficacy
McKool Smith and The Lanier Law Firm, along with Texas Attorney General Ken Paxton, have filed a lawsuit on behalf of the State of Texas against Bristol-Myers Squibb Company and several Sanofi entities, alleging the companies failed to disclose the efficacy and safety profile of the drug Plavix, which is used as a blood thinner.
Under this partnership, Antheia will leverage TAPI's next-generation fermentation capabilities and manufacturing facilities in Europe to further commercialise its pipeline of biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs).
Qure.ai Partners with Microsoft to Expand Lung Cancer AI Access in the US
Qure.ai has partnered with Microsoft to broaden access to its advanced lung cancer detection and management AI suite across the US. The collaboration integrates Qure.ai’s LLM- and agentic AI–driven tools into clinical workflows, helping radiology and pulmonology teams accelerate patient detection, diagnosis, and treatment pathways.
GSK and LTZ Collaborate to Advance Novel Myeloid Cell Engagers in Oncology
Leveraging LTZ’s novel immune-engager platform and GSK’s oncology expertise, the partnership aims to deliver potent, safer cancer therapies that can be administered in community settings, supporting GSK’s strategy to advance transformative medicines through cutting-edge technologies.
Ocuvex Resubmits CRL to FDA for PDP-716 NDA, SPARC Reveals
Sun Pharma Advanced Research Company (SPARC) announced that Ocuvex Therapeutics has resubmitted a Complete Response Letter (CRL) to the US Food and Drug Administration (FDA) for the New Drug Application (NDA) of PDP-716.
EY-OPPI Report Outlines Three-Pronged Strategy to Unlock India's USD 450 Billion Pharma Potential
India’s pharma industry will need to move from a volume-led approach to a model driven by value, innovation and stronger collaboration across the ecosystem if it is to achieve its projected value of USD 450 billion by 2047, says EY–OPPI Report.
Xenetic Biosciences has extended its research collaboration with the laboratory of Dr Alexey Stepanov, Institute Investigator at Scripps Research to advance the company’s R&D programme, evaluating the combined use of systemic DNase I and CAR T-cell therapies for difficult-to-treat cancers.
Lunit and Labcorp Partner to Advance AI-Driven Digital Pathology Research
Lunit and Labcorp have collaborated to accelerate innovation in Artificial Intelligence (AI)-driven digital pathology, combining Labcorp’s clinical and pathology expertise with Lunit’s advanced AI technologies to enhance tumour microenvironment analysis and support next-generation oncology research.
India Unveils its First Indigenous CRISPR-based Gene Therapy 'BIRSA 101' for Sickle Cell Disease
India has formally begun its decisive journey towards becoming a Sickle Cell Disease–free nation, with Union Minister of State for Science & Technology Dr. Jitendra Singh launching the country's first indigenous CRISPR-based gene therapy for the condition.
Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
Tsingke Biotech showcased its accelerated protein and antibody production platform at PEGS Europe 2025, announcing capabilities to generate proteins in as little as three days and antibodies within seven—offering a boost to biopharma developers seeking faster drug discovery timelines.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy